What Antibiotics Treat Coagulase Negative Staph UTI?

Nitrofurantoin and trimethoprim-sulfamethoxazole (TMP-SMX) are the most commonly recommended first-line antibiotics for urinary tract infections caused by coagulase-negative staphylococci (CoNS), particularly in uncomplicated cases. But the best choice depends heavily on which CoNS species is involved, whether the infection is community-acquired or hospital-acquired, and how resistant the specific strain turns out to be. The resistance landscape among CoNS is more complicated than most people realize, and it shapes treatment decisions in ways that differ from the typical E. coli UTI playbook.

Which CoNS Species Are Causing the Infection Matters

Not all coagulase-negative staphylococci behave the same way in the urinary tract, and the species behind the infection significantly influences which antibiotics will work. The most well-known CoNS uropathogen is Staphylococcus saprophyticus, which is the second most common cause of UTIs in young women, responsible for roughly one in ten cases in that population.¹ S. saprophyticus tends to cause straightforward, community-acquired infections in otherwise healthy people. It has a specific virulence trick: it produces urease, an enzyme that helps it survive and cause damage in the bladder.²

In hospital settings, the picture shifts. Staphylococcus epidermidis and Staphylococcus haemolyticus become the dominant CoNS species causing UTIs, often in patients with urinary catheters or other medical devices.³ In one prospective study of catheterized patients, CoNS accounted for about a fifth of all bacteriuria episodes, with S. epidermidis being the most frequent species.⁴ These healthcare-associated strains tend to carry far more antibiotic resistance than community-acquired S. saprophyticus, which is why distinguishing the species is not just an academic exercise.

First-Line Antibiotics for Uncomplicated CoNS UTIs

For a straightforward, community-acquired CoNS UTI, especially one caused by S. saprophyticus in a young woman, the standard empiric options mirror what you would use for a typical uncomplicated UTI. Nitrofurantoin and TMP-SMX are the workhorses. A study of S. saprophyticus urinary isolates found that susceptibility to nitrofurantoin was 100%, trimethoprim susceptibility was 97%, and TMP-SMX susceptibility was 98%.⁵ Those are excellent numbers and support the continued use of these drugs as empiric therapy before culture results come back.

Typical regimens include nitrofurantoin 100 mg taken orally twice daily for five days, or TMP-SMX twice daily for three days. A single dose of fosfomycin trometamol is another option, and it is sometimes preferred for pregnant patients with lower UTIs because of its favorable safety profile and convenient dosing.⁶ The key advantage of nitrofurantoin is that resistance to it remains extremely rare among CoNS urinary isolates, even in settings where resistance to other antibiotics is climbing.

One important caveat: nitrofurantoin only achieves therapeutic concentrations in the urine, not in the blood or kidneys. If the infection has spread beyond the bladder to become pyelonephritis, or if there is any suspicion of bloodstream infection, nitrofurantoin is not the right choice. TMP-SMX or a fluoroquinolone can reach tissue concentrations and would be more appropriate in that scenario.

When Resistance Complicates the Picture

The relatively rosy resistance numbers for S. saprophyticus do not extend to all CoNS species. Once you step into the world of S. epidermidis and S. haemolyticus, resistance rates jump dramatically, and the easy first-line options become less reliable. In one study of outpatient women with CoNS UTIs, resistance to trimethoprim reached about 37%, and resistance to gentamicin was around 33%. Even fluoroquinolone resistance was meaningful, with roughly 17% of isolates resisting ciprofloxacin. Nitrofurantoin fared best in that group too, with resistance under 9%.⁷

The resistance problem gets worse in healthcare settings. A study of CoNS isolates from various clinical specimens found that nearly three-quarters were resistant to amoxicillin and about 70% were resistant to oxacillin. The only antibiotics with consistently low resistance were vancomycin (about 3% resistance) and linezolid (under 1%).⁸ This means that many standard beta-lactams, the class that includes penicillins and many cephalosporins, simply will not work against a large share of CoNS infections picked up in a hospital.

The Methicillin Resistance Problem

A major reason beta-lactams often fail against CoNS is the widespread presence of the mecA gene, which encodes resistance to methicillin and, by extension, to most other beta-lactam antibiotics. This gene is strikingly common among CoNS. One study using PCR testing found it in about 71% of clinical CoNS isolates.⁹ An Iranian surveillance study detected it in about 75% of isolates.¹⁰ An older but still relevant survey found the gene in nearly 97% of methicillin-resistant clinical CoNS strains across nine different species.¹¹

What this means practically is that if you are dealing with a healthcare-associated CoNS UTI, especially from a catheterized patient, there is a good chance that penicillins, amoxicillin, and many cephalosporins will be useless. This is a fundamentally different situation from a community-acquired S. saprophyticus UTI in a young woman, where beta-lactam resistance is much less common. The species matters, and so does where the infection was acquired.

Fluoroquinolones and Their Limits

Ciprofloxacin and other fluoroquinolones are sometimes used for CoNS UTIs, and they can be effective, but the picture is mixed. Against S. saprophyticus specifically, ciprofloxacin susceptibility has been reported at 100%.⁵ That is reassuring, but fluoroquinolones are generally not first-line for uncomplicated UTIs due to their side-effect profile and the desire to preserve them for more serious infections.

Against other CoNS species, fluoroquinolone resistance is more significant and varies by species. S. haemolyticus shows much higher fluoroquinolone resistance than S. epidermidis. One study found 43% of S. haemolyticus strains were resistant to fluoroquinolones, compared to 11% of S. epidermidis.¹² Methicillin-resistant strains of S. haemolyticus were even more likely to be ciprofloxacin-resistant. Cross-resistance between different fluoroquinolones was common, so switching from ciprofloxacin to levofloxacin would not necessarily solve the problem if the strain was already resistant. Among fluoroquinolone-resistant strains, none of the tested drugs reached concentrations high enough to treat systemic infections reliably, though urinary concentrations can be considerably higher than blood levels.

Reserve Antibiotics for Tough Cases

When resistance knocks out the first-line agents and fluoroquinolones, clinicians turn to drugs normally reserved for more serious staphylococcal infections. Vancomycin has long been the safety net for methicillin-resistant staphylococci, though it requires intravenous administration and is usually reserved for complicated or systemic infections rather than simple cystitis. The good news is that vancomycin resistance among CoNS remains very low.

Linezolid and daptomycin represent the next tier. A global systematic review and meta-analysis found that CoNS resistance to both linezolid and daptomycin was around 0.3%, the lowest of any antibiotics studied. Tigecycline showed slightly higher resistance at about 1.6%.¹³ Daptomycin in particular has been highlighted for its effectiveness against CoNS bacteremia, and researchers have noted that ongoing heavy use of linezolid has begun to generate resistant strains in some settings.¹⁴

These reserve agents are almost never needed for a simple CoNS bladder infection. They come into play when the infection involves a bloodstream component, when the patient is severely immunocompromised, or when culture results show resistance to everything else. Daptomycin, like vancomycin, requires IV administration. Linezolid is available orally, which makes it potentially useful for outpatient treatment of resistant cases, but cost and side effects limit its casual use.

Why Catheter-Related CoNS UTIs Are Harder to Treat

Catheter-associated CoNS UTIs present a distinct challenge beyond just antibiotic resistance. Many CoNS species, S. epidermidis in particular, are prolific biofilm producers. A biofilm is essentially a structured community of bacteria encased in a slimy matrix that sticks to surfaces like catheter tubing. Bacteria living inside a biofilm are dramatically harder to kill with antibiotics than bacteria floating freely in urine. Research on S. epidermidis recovered from indwelling catheters has shown that these clinical strains have genetic changes that enhance their ability to attach to surfaces, release extracellular DNA, and build robust biofilms.¹⁵

The practical consequence is that antibiotics alone may not clear a catheter-associated CoNS UTI. Removing or replacing the catheter is often an essential part of treatment. Without taking out the colonized device, the biofilm acts as a persistent reservoir that seeds new bacteria into the urine even while you are pouring antibiotics into the patient. This is one of those situations where the treatment is not just about picking the right drug but also about addressing the hardware.

Pregnant Women and CoNS UTIs

Pregnancy adds an extra layer of complexity. CoNS have been identified as a leading cause of asymptomatic bacteriuria in some studies of pregnant women, accounting for about a third of isolates in one Ethiopian cohort.¹⁶ Asymptomatic bacteriuria during pregnancy is routinely treated because untreated infections carry risks for both mother and baby.

Antibiotic options narrow during pregnancy because several standard UTI drugs are off-limits. Fluoroquinolones are generally avoided due to concerns about cartilage development in the fetus. TMP-SMX is typically avoided in the first trimester and near term. Nitrofurantoin is considered acceptable for most of pregnancy but is generally avoided near delivery. Fosfomycin, with its single-dose convenience, is often a practical choice for pregnant patients with uncomplicated lower CoNS UTIs. The susceptibility patterns found in that Ethiopian study showed that norfloxacin had the highest susceptibility rate at about 65%, but its use would be restricted in pregnancy. Gentamicin and cefotaxime had moderate susceptibility, while ampicillin susceptibility was very low.¹⁶ These numbers underscore how important culture-guided therapy is during pregnancy, where the drug options are already limited.

Getting the Right Diagnosis

One underappreciated challenge with CoNS UTIs is simply confirming that the CoNS in the urine culture is the actual pathogen and not a contaminant. CoNS live on the skin and regularly sneak into urine samples, especially those collected without careful technique. Labs have traditionally been quick to dismiss CoNS in urine as contamination, which sometimes means real infections get overlooked.

S. saprophyticus is the exception. Labs are well aware that it is a genuine uropathogen, and a positive culture for S. saprophyticus in a symptomatic young woman is taken at face value. For other CoNS species, especially S. epidermidis or S. haemolyticus, clinicians generally look for supporting evidence: symptoms, a high colony count, a repeat positive culture, or the presence of risk factors like a urinary catheter. In catheterized patients, the threshold for taking CoNS seriously is lower because these organisms are known catheter-associated pathogens.

Detecting methicillin resistance accurately also has its quirks. Automated susceptibility-testing systems can sometimes overcall methicillin resistance in CoNS. One evaluation of a widely used automated system found that while it detected mecA-positive methicillin resistance with about 99% sensitivity, the specificity was only about 65% when using standard breakpoints, meaning it flagged some mecA-negative strains as resistant when they were not.¹⁷ This could lead to unnecessarily escalating therapy to vancomycin or other reserve drugs when a beta-lactam might have worked. When in doubt, molecular testing for the mecA gene gives the most reliable answer.

Resistance Patterns Vary by Geography

Antibiotic resistance is not uniform across the world, and this is especially true for CoNS. The near-perfect susceptibility rates for nitrofurantoin and TMP-SMX reported in S. saprophyticus isolates from Australia or Europe may not hold in other regions. Data from different countries show substantially different resistance profiles for CoNS urinary isolates. In some Middle Eastern and South Asian settings, trimethoprim resistance in CoNS runs well above 30%, which would make TMP-SMX a poor empiric choice in those areas.⁷ Local antibiograms, the cumulative susceptibility data that hospitals and regions compile, are the most reliable guide for empiric prescribing.

Even within a single country, resistance can differ between community and hospital isolates of the same species. Hospital-acquired S. epidermidis strains tend to carry more resistance genes than community strains, partly because hospitals are high-pressure environments where antibiotics are used heavily and resistant clones spread more easily. If you are treating a CoNS UTI, knowing where and how the patient picked up the infection gives you a meaningful head start on guessing which antibiotics will work before the culture results come back.

A Practical Decision Framework

Pulling this together, the antibiotic choice for a CoNS UTI can be broken down by clinical scenario:

Uncomplicated cystitis, likely S. saprophyticus: Nitrofurantoin or TMP-SMX are reliable empiric choices. Fosfomycin is an alternative, especially useful as a one-dose option.
Catheter-associated or hospital-acquired CoNS UTI: Culture and sensitivity testing should drive the choice. Nitrofurantoin remains a reasonable empiric start for lower tract symptoms while awaiting results, but expect higher resistance rates. Catheter removal or exchange is often necessary alongside antibiotics.
Methicillin-resistant CoNS UTI (confirmed on testing): Beta-lactams are out. Nitrofurantoin still works for bladder infections, since methicillin resistance does not affect nitrofurantoin activity. For complicated or upper tract infections, vancomycin IV is the standard. Linezolid or daptomycin are backup options if vancomycin is not suitable.
Pregnant patients: Fosfomycin or nitrofurantoin (with trimester-appropriate precautions) are first-line. Culture guidance is especially important because the drug menu is limited.

The consistent theme across all these scenarios is that nitrofurantoin holds up remarkably well against CoNS urinary isolates regardless of species, setting, or methicillin-resistance status. Its main limitation is anatomical, not microbiological: it only works in the bladder. For anything beyond simple cystitis, the antibiotic choice depends on the susceptibility results your lab sends back, and on whether there is a piece of hardware in the urinary tract that needs to come out.